Non-invasive microbiome-derived multi-omic biomarkers for the early-stage detection and stratification of Parkinson’s disease

Parkinson’s disease (PD) research benefits from knowledge of disease-specific risk and resilience factors and elucidation of pathophysiological concepts on the emergence of neurodegeneration. Presently the propagation of a-synuclein aggregation in PD is proposed to start in the periphery, i.e. in the enteric nervous system and the olfactory bulb. Aberrations within the gastrointestinal and nasal microbiomes may play a role in the initiation of this process. This is of particular relevance in relation to the development of future disease-modifying neuroprotective therapies that would require intervention at the earliest stages of disease but also to identify preventive strategies for the conversion to, i.e. manifest PD. Therefore, MiBiPa aims to have a durable and significant impact on better identification, prevention, treatment and management of PD.

ELU-1-913FE2-1

MiBiPa

2017-09-01

2024-12-31

FNR, Michael J. Fox Foundation for Parkinson’s research, Deutsche Forschungsgesellschaft DFG (Grant number Michael J. Fox Foundation for Parkinson’s research (grant ID: 14701) Deutsche Forschungsgesellschaft DFG (grant ID: MO 2088/5-1) FNR (grant ID: C16/BM/11333923/MiBiPa))

IMI2

Parkinson’s disease microbiome biomarker